There are contraindications! Be sure to consult your doctor before taking any medication!
Bromatapp consists of Brompheniramine Maleate, Phenylpropanolamine Hydrochloride.
Phenylpropanolamine Hydrochloride - Bromatapp (Phenylpropanolamine Hydrochloride) has been withdrawn in Canada. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug.
Indication: For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity.
Bromatapp (Phenylpropanolamine Hydrochloride) (PPA), a sympathomimetic agent structurally similar to pseudoephedrine, is used to treat nasal congestion. Bromatapp (Phenylpropanolamine Hydrochloride) is found in appetite suppressant formulations and with guaifenesinin in cough-cold formulations. In 2000, the FDA requested that all drug companies discontinue marketing products containing phenylpropanolamine, due to an increased risk of hemorrhagic stroke in women who used phenylpropanolamine.
Pharmaceutical active ingredients containing related brand and generic drugs, medications or other health care products: